Genentech's OpRegen Study Targets Geographic Atrophy in AMD with Subretinal Delivery
Genentech is conducting a study to evaluate the safety and activity of OpRegen delivered via subretinal surgery in patients with geographic atrophy secondary to AMD.
Phase III
Ophthalmology / Geographic Atrophy
Status
Active
Sponsor
Roche
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of Genentech's OpRegen for geographic atrophy positions the company to potentially enhance its portfolio in the competitive AMD market. Success in this innovative delivery method could lead to significant advancements in treatment options and market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding the operational feasibility of the EarlySight Cellularis® Discovery device.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.